The OptIMMize-1 phase III study (NCT04435600) evaluated the efficacy and safety of risankizumab (an IL-23 inhibitor) vs. ustekinumab over 52 weeks in paediatric patients with moderate-to-severe psoriasis across 4 study parts, with Part 2 randomising patients 2:1 to risankizumab vs. ustekinumab.
At week 16 in Part 2 (risankizumab n=54 vs. ustekinumab n=28), sPGA0/1 rates were 79.6% vs. 75.0%, PASI75 rates were 85.2% vs. 85.7%, PASI90 rates were 64.8% vs. 60.7%, and PASI100 rates were notably higher with risankizumab (40.7% vs. 17.9%); efficacy was maintained or improved at week 52, with a safety profile consistent with adult studies.
The study was open-label in three of four parts, limiting blinding; the comparator arm (ustekinumab) in Part 2 was relatively small (n=28); and no placebo-controlled comparison was included.
Risankizumab appears effective and well tolerated in paediatric moderate-to-severe psoriasis, with meaningful skin clearance, itch, and quality-of-life improvements sustained to 52 weeks, supporting its use as an advanced therapy option in this population.
Explore related topics